199 related articles for article (PubMed ID: 12512837)
1. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.
Ueda S; Ikeda H; Mizuki M; Ishiko J; Matsumura I; Tanaka H; Shibayama H; Sugahara H; Takai E; Zhang X; Machii T; Kanakura Y
Int J Hematol; 2002 Dec; 76(5):427-35. PubMed ID: 12512837
[TBL] [Abstract][Full Text] [Related]
2. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
Frost MJ; Ferrao PT; Hughes TP; Ashman LK
Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
[TBL] [Abstract][Full Text] [Related]
3. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase.
Kitayama H; Tsujimura T; Matsumura I; Oritani K; Ikeda H; Ishikawa J; Okabe M; Suzuki M; Yamamura K; Matsuzawa Y; Kitamura Y; Kanakura Y
Blood; 1996 Aug; 88(3):995-1004. PubMed ID: 8704259
[TBL] [Abstract][Full Text] [Related]
4. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.
Kitayama H; Kanakura Y; Furitsu T; Tsujimura T; Oritani K; Ikeda H; Sugahara H; Mitsui H; Kanayama Y; Kitamura Y
Blood; 1995 Feb; 85(3):790-8. PubMed ID: 7530509
[TBL] [Abstract][Full Text] [Related]
5. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
6. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
[TBL] [Abstract][Full Text] [Related]
7. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
Nakagomi N; Hirota S
Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
[TBL] [Abstract][Full Text] [Related]
8. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
[TBL] [Abstract][Full Text] [Related]
9. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.
Akin C; Brockow K; D'Ambrosio C; Kirshenbaum AS; Ma Y; Longley BJ; Metcalfe DD
Exp Hematol; 2003 Aug; 31(8):686-92. PubMed ID: 12901973
[TBL] [Abstract][Full Text] [Related]
10. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
Liao AT; Chien MB; Shenoy N; Mendel DB; McMahon G; Cherrington JM; London CA
Blood; 2002 Jul; 100(2):585-93. PubMed ID: 12091352
[TBL] [Abstract][Full Text] [Related]
12. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.
Ma Y; Zeng S; Metcalfe DD; Akin C; Dimitrijevic S; Butterfield JH; McMahon G; Longley BJ
Blood; 2002 Mar; 99(5):1741-4. PubMed ID: 11861291
[TBL] [Abstract][Full Text] [Related]
13. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
[TBL] [Abstract][Full Text] [Related]
15. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
16. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site.
Tsujimura T; Hashimoto K; Kitayama H; Ikeda H; Sugahara H; Matsumura I; Kaisho T; Terada N; Kitamura Y; Kanakura Y
Blood; 1999 Feb; 93(4):1319-29. PubMed ID: 9949175
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
18. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
Maulik G; Bharti A; Khan E; Broderick RJ; Kijima T; Salgia R
J Environ Pathol Toxicol Oncol; 2004; 23(4):237-51. PubMed ID: 15511212
[TBL] [Abstract][Full Text] [Related]
19. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
